Ascendis Pharma received orphan drug exclusivity from the Food and Drug Administration for Yuviwel, a treatment for a rare genetic disorder. The Danish biopharmaceutical company also said Monday that ... The Manila Times: Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children Seeking Alpha: Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia Nasdaq: U.S.
Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia Expanded Indication in the U.S. Now Includes Children of all ages with Achondroplasia BioMarin conducted a randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating the safety and ... U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
